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Background. Telemedicine use is increasing in many specialties, but its impact on clinical outcomes in infectious diseases has 
not been systematically reviewed. We reviewed the current evidence for clinical effectiveness of telemedicine infectious diseases 
consultations, including outcomes of mortality, hospital readmission, antimicrobial use, cost, length of stay, adherence, and patient 
satisfaction.
Methods. We queried Ovid MEDLINE 1946-, Embase.com 1947-, Scopus 1823-, Cochrane Database of Systematic Reviews 
(CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov 1997- through August 5, 2019, for 
studies looking at clinical outcomes of infectious diseases in the setting of telemedicine use. We did not restrict by language or year 
of publication. Clinical outcomes searched included 30-day all-cause mortality, 30-day readmissions, patient compliance/adherence, 
patient satisfaction, cost or cost-effectiveness, length of hospital stay, antimicrobial use, and antimicrobial stewardship. Bias was as-
sessed using standard methodologies. PROSPERO CRD42018105225.
Results. From a search pool of 1154 studies, only 18 involved telemedicine infectious diseases consultation and our selected clinical 
outcomes. The outcomes tracked were heterogeneous, precluding meta-analysis, and the majority of studies were of poor quality. Overall, 
clinical outcomes with telemedicine infectious diseases consultation seem comparable to in-person infectious diseases consultation.
Conclusions. Although in widespread use, the clinical effectiveness of telemedicine infectious diseases consultations has yet to 
be sufficiently studied. Further studies, or publication of previously collected and available data, are warranted to verify the cost-ef-
fectiveness of this widespread practice.
Keywords.  clinical outcomes; infectious diseases consultation; mortality; systematic review; telemedicine.
Systematic review registration.  PROSPERO CRD42018105225.
According to recent estimates, infectious diseases may be the 
third leading cause of death in the United States [1]. However, 
underserved and/or economically disadvantaged areas may not 
have access to infectious diseases (ID) physicians (up to 45% of 
US hospitals) to help treat these infections [2]. This is problem-
atic because consultation with ID physicians significantly re-
duces mortality for numerous infections [3, 4]. Providing access 
to ID expertise in underserved/rural areas could substantially 
reduce mortality and improve clinical outcomes. As 51% of ID 
fellowship programs did not fill in 2015 [5, 6], access to ID ex-
pertise may be limited. With a shortage of ID physicians, it may 
not be possible for remote locations to employ an ID physician, 
that is, what is seen in current practice. Telemedicine could po-
tentially expand ID expertise to underserved areas.
Telemedicine is widely used in many subspecialties. Studies 
show that telemedicine reduces mortality in progressive and in-
tensive care units and in very low birth weight infants [7–9], 
but its effectiveness for important clinical outcomes in infec-
tious diseases is lacking. To date, there has been no synthesis 
of evidence for the use of telemedicine for infectious diseases 
consultation. Our systematic review addresses this deficiency 
by answering the following question: In patients with infectious 
diseases, do telemedicine ID consultations improve the clinical 
outcomes of mortality, readmission, patient adherence/compli-
ance, patient satisfaction, cost, cost-effectiveness, length of stay, 
antibiotic use, or antibiotic stewardship?
METHODS
Data Sources and Searches
A medical librarian (L.H.Y.) searched the literature for re-
cords including the concepts of infectious diseases, infection, 
antimicrobial stewardship, antibiotic stewardship, antifungal 
stewardship, antiviral stewardship, telemedicine and videocon-
ferencing, and consultation/consult. The librarian created search 
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strategies using a combination of keywords and controlled vo-
cabulary in Ovid Medline 1946-, Embase 1947-, Scopus 1823-, 
Cochrane Database of Systematic Reviews (CDSR), Cochrane 
Central Register of Controlled Trials (CENTRAL), and 
Clinicaltrials.gov 1997-. All search strategies were completed 
in November 2018, then updated in August 2019. The protocol 
was registered with the international prospective register of sys-
tematic reviews (PROSPERO), in accordance with PRISMA-P 
guidelines (PROSPERO CRD42018105225) [10]. The protocol 
for this systematic review has been previously described [11].
Aim
Our goal was to assess the effectiveness of telemedicine ID con-
sultation for a range of clinical outcomes (enumerated below) as 
compared with either (1) no ID consultation or (2) other modal-
ities of ID consultation (eg, in person). Clinical outcomes con-
sidered included 30-day all-cause mortality, readmission within 
30 days of discharge from an initial hospitalization with an in-
fection, patient compliance/adherence, patient satisfaction, cost 
or cost-effectiveness, length of hospital stay, antimicrobial use, 
and/or antimicrobial stewardship.
There were no language or year of publication restrictions. 
Translation of non-English-language abstracts was under-
taken, as required, though ultimately all full-text articles were 
in English. Conference abstracts were excluded if sufficient out-
come and bias data could not be extracted. REDCap was used 
for data entry.
Study Selection
After removal of duplicate results, titles and abstracts were re-
viewed for relevance to the research question by J.P.B. See 
Figure 1 for the study flowchart from title/abstract review to final 
inclusion. Articles were excluded if any of the following condi-
tions was met: (1) infections not studied, (2) no consultations, (3) 
consultations not performed for infection, (4) no telemedicine, 
(5) noninterventional (eg, viewpoint articles, commentaries, 
etc.), (6) infectious diseases outcomes indistinguishable from 
other consultations, (7) no prespecified outcomes of interest 
tracked, or (8) abstract only with insufficient methodological or 
results reporting. Studies that were not excluded underwent in-
dependent, blinded, full-text review by J.P.B. and G.A.C.
Definitions
Telemedicine was defined as remote clinical services adminis-
tered using a technological medium. This included face-to-face 
video chat (physician-to-physician or physician-to-patient), 
voice chat after review of electronic health records, or elec-
tronic health record documentation after remote chart review 
without direct voice or video contact with physician or patient. 
Antibiotic stewardship was quantified as either antibiotic costs 
or antibiotic appropriateness, as judged by the authors of the 
individual studies.
Data Extraction
In a blinded fashion, 2 authors (J.P.B.  and G.A.C.) independ-
ently extracted data from full-text articles. Data extracted in-
cluded study quality, clinical or system-level outcome tracked, 
percent change or proportion experiencing each clinical out-
come, numbers of patients, age group, consultant specialty, type 
of telemedicine, study location, whether infection was con-
firmed by laboratory results, and type and risk of bias.
Data extraction disputes were settled by a third reviewer 
(S.A.F.—also blinded), and in cases requiring further adjudica-
tion, a group session of all 3 reviewers was convened.
Quality Assessment
Risk of bias was independently reviewed by 2 reviewers 
(J.P.B. and G.A.C.) in a blinded fashion. Disputes were resolved 
by a third reviewer (S.A.F.—also blinded), and in cases of con-
tinued disagreement, the 3 reviewers met for adjudication. 
Bias determination was guided by the Cochrane Consumers 
and Communication Review Group Study Quality Guide or 
Newcastle-Ottawa scale [12, 13]. Using the Newcastle-Ottawa 
Scale, the case–control and cohort studies were given star ratings 
Reasons to exclude:
no infections, no consultations, consultations
not for infection, no telemedicine, non-
interventional study, infectious diseases
outcomes indistinguishable from those of  other
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in 3 categories —Selection (maximum 4 stars), Comparability 
(maximum 2 stars), and Outcome (maximum 3 stars)—with 
a maximum score of 9 stars [13]. The quality of case–control 
and cohort studies was adjudicated based on previously pub-
lished guidance [14]: good quality: Selection ≥3 stars AND 
Comparability ≥1 stars AND Outcome ≥2 stars; fair quality: 
Selection 2 stars AND Comparability ≥1 stars AND Outcome 
≥2 stars; poor quality: Selection ≤1 Star OR Comparability 0 
stars OR ≤1 stars.
Analysis
Per protocol [11], prespecified subgroup analyses included 
outcomes by age (children <18  years vs adult ≥18  years), tel-
emedicine consultant being ID trained or not, infection type, 
type of telehealth/telemedicine intervention (eg, face-to-face, 
asynchronous, etc.), study location (US vs non-US), number 
of ID consultations (ie, days physician interacted with patient/
provider), and culture- or laboratory-confirmed infection vs 
presumed infection. Due to the limited number of studies, qual-
itative/narrative synthesis was performed.
RESULTS
A total of 1328 results were found using our initial search 
strategy, which was completed in November 2018. A  total of 
284 duplicate records were identified using Endnote’s automatic 
duplication finder, and another 31 duplicates were removed by 
manual review, leaving 1013 unique citations in the project li-
brary. One additional study was identified after reviewing ref-
erences of full-text article reviews, for a total of 1014 search 
results. We updated our search on August 5, 2019. With this 
update, an additional 140 results were found, leaving a total of 
1154 results to be reviewed. Fully reportable searches can be 
found in Appendix 1.
Of the 1154, none of the clinical trials identified only from 
ClinicalTrials.gov (n  =  21) had available results. Of the re-
maining excluded articles, the reasons for exclusion are listed in 
Figure 1 and Supplementary Table 1. A total of 18 articles were 
relevant to the research question and underwent full-text review. 
From these articles, clinical outcomes tracked included 30-day 
mortality after an infection (16.7%, n = 3), readmission within 
30 days after discharge from the initial hospitalization with an 
infection (5.6%, n = 1), patient compliance/adherence (11.1%, 
n = 2), patient satisfaction (50.0%, n = 9), cost or cost-effective-
ness (22.2%, n = 4), length of stay (27.8%, n = 5), and antimicro-
bial use (27.8%, n = 5). Meta-analysis was not performed due to 
the low number of studies with any 1 outcome.
Biases/Quality Assessment
There were 2 (11.1%) randomized clinical trials, 2 case–control 
studies (11.1%), and 14 (77.8%) cohort studies. Both random-
ized controlled trials had high risk of bias in 3 categories and 
unclear risk in 2 others [15, 16]. Using the Newcastle-Ottawa 
Scale, both the case–control studies and 8 cohort studies were 
rated as poor quality. The remaining 6 cohort studies were rated 
as good quality (Supplementary Table 2).
Study Characteristics
Most studies were performed only in adults (n  =  13, 72.2%). 
Consultant specialty was infectious diseases in only 38.9% 
(n = 7). Infections studied included pneumonia (n = 4), urinary 
tract infection (n = 5), sepsis (n = 3), bacteremia (n = 3), en-
docarditis (n = 2), skin and soft tissue infections (n = 3), upper 
respiratory infections (n = 4), and other (n = 12). More than 1 
infection type could be studied in each article.
The most common type of telemedicine was face-to-face vid-
eoconferencing with the patient in 72.2% (n  =  13), followed 
by telephone only (16.7%, n = 3), physician-to-physician only 
(5.6%, n = 1), and 1 study in which the telemedicine type could 
not definitively be determined.
Just over half (n  =  10) were based in the United States, 
and 8 in other countries (Europe = 4, Australia = 2, Asia = 1, 
Canada  =  1). Infections were confirmed by culture in 61.1% 
(n = 11) of studies.
Clinical Outcomes
Patient satisfaction with telemedicine was the most commonly 
reported outcome, and the percentage of patients satisfied 
with telemedicine was above 97% in 6/7 studies [17–22], with 
1 study reporting patient satisfaction of 69% (Table 1) [16]. 
Two additional studies reported patient satisfaction but pro-
vided a mean satisfaction score without a numerator and de-
nominator for the number of patients reporting the outcome, 
though the mean score in both studies was indicative of high 
satisfaction [23, 24].
Mortality was higher in the telemedicine group in 2 studies 
and lower in the other 2 studies reporting this outcome (range 
for all studies, 0%–22%) [15, 25–27], with 1 study reporting 
90-day instead of 30-day mortality (higher mortality in the 
control group) (Table 1) [27]. Only 1 of these studies was sta-
tistically significant, with lower mortality in patients receiving 
in-person rather than telephone-only ID consults [26]. Length 
of stay was shorter in the telemedicine group in 4/5 studies 
[24–27] and equivalent in 1 study (range, 2.6–30 days) (Table 
1) [28].
Readmission and adherence/compliance were similar be-
tween telemedicine and nontelemedicine groups (Table 1) [15, 
19, 27]. Costs were lower in the telemedicine groups, but based 
on projections that may not be generalizable [15, 24, 28, 29]. 
Antibiotic use was similar between telemedicine groups and 
controls [25, 27, 30–32].
DISCUSSION
Based on the available, albeit limited, evidence, telemedicine 
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clinical outcomes of mortality, length of stay, readmission, ad-
herence, cost, and antimicrobial use. However, there were few 
relevant studies tracking our prespecified clinical outcomes, 
and the majority were of poor quality. Without more robust 
data quality and availability, it is difficult to draw any firm 
conclusions.
Few studies have been published demonstrating effectiveness 
of telemedicine for infectious diseases consultation. Infection 
types that have been studied, as well as the settings in which 
telemedicine has been used, have been varied. As telemedicine 
continues to expand, clinicians and researchers should consider 
publication of their already existing data to document the clin-
ical effectiveness needed to validate this model of care and costs. 
In addition, researchers must report their processes of telemed-
icine ID implementation so that what works in 1 study can be 
applied more broadly, understanding that adaptations will likely 
be required. In this rapidly blossoming field, we must publish 
best practices using standardized reporting for effective and 
implementable telemedicine ID consults so that our patients 
reap maximum benefits.
Our review is limited in scope by our chosen clinical out-
comes. Among the excluded studies (data not shown) were 
studies looking at the use of telemedicine to care for patients 
with hepatitis C or HIV (among others). These studies are im-
portant and relevant to the telemedicine ID consultation land-
scape, but did not track our prespecified clinical outcomes. The 
clinical outcomes we chose are of interest to inpatient settings 
(mortality, readmission, length of stay) and administrators 
(cost, patient satisfaction, readmission, antimicrobial use, mor-
tality). A summary of the currently available data may help in 
the adoption of inpatient telemedicine ID services by inpatient 
physicians and administrators, should the data become more 
robust.
Infectious diseases consultation can save lives, and with al-
most half of US hospitals without ID physician access [2], tel-
emedicine has great potential to fill this gap. Before its wide 
adoption, it should be robustly evidence-based. Important 
questions in this arena are related to which type of telemedi-
cine is required, how frequently telemedicine visits must be 
performed (eg, daily, 1-time), and what level of infectious 
Table 1. Clinical Outcomes of Telemedicine Infectious Diseases Consultation as Compared With Control for Individual Studies From Systematic Review
Study (First Author, Reference Number) Control Intervention Group Size (Control, Intervention) Telehealth Type
Mortality, %
 Assimacopoulos [35] 5 1 59, 48 Face-to-face video
 Chen [15] 1 0 150, 148 Telephone only
 Saunderson [26] 12 22 294, 183 Telephone only
 Monkowski [27] 10 5 73, 171 Face-to-face video
Readmission, %
 Monkowski [27] 17 11 73, 171 Face-to-face video
Patient satisfaction, %
 Cuadrado [23] n/a Unable to determine 0, 63 Face-to-face video
 Garrett [17] n/a 100 0, 28 Telephone only
 Leόn [16] n/a 69 41, 42 Face-to-face video
 Mashru [21] n/a 98 0, 76 Face-to-face video
 Nazareth [18] n/a 100 559, 50 Face-to-face video
 Saifu [19] n/a 97 0, 43 Face-to-face video
 You [20] n/a 100 0, 96 Face-to-face video
 Eron [24] n/a Unable to determine 25, 25 Face-to-face video
 Staicu [22] n/a 98 0, 50 Face-to-face video
Antimicrobial use, %
 Mehrotra [30] 77 99 7545, 574 Face-to-face video
 Rincon [31] n/a 74 0, 5437 Other
 Shi [32] 53 52 1128629, 38839 Face-to-face video
Patient adherence/compliance, %
 Chen [15] 88 95 150, 148 Telephone only
 Saifu [19] n/a 76 0, 43 Face-to-face video
Length of hospital stay, d 
 Assimacopoulos [35] 10.7 6.5 59, 48 Face-to-face video
 Ceradini [28] 8.4 8.4 683, 531 Physician-to-physician
 Saunderson [26] 29 30 294, 183 Telephone only
 Eron [24] 8 2.6 25, 25 Face-to-face video
 Monkowski [27] 14 9 73, 171 Face-to-face video
Antimicrobial use, d
 Assimacopoulos [35] 13.4 6.9 59, 48 Face-to-face video
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diseases physician involvement is optimal to achieve the best 
clinical outcomes. For example, a recent study showed that an 
algorithm-based care model for Staphylococcus aureus bacte-
remia achieved noninferior outcomes to usual care [33]. With 
this in mind, one must ask what the minimum unit of efficacy 
is for infection management. Whether that is in-person con-
sultation, telemedicine consultation, Extension for Community 
Healthcare Outcomes (ECHO)–like models, algorithm-based 
care, or another care model has yet to be determined. In ad-
dition, it is unknown whether certain infections will require 
different levels of ID input for optimal outcomes. Notably, curb-
side consultations are often inaccurate and potentially harmful 
[34], which may have implications for care delivery methods 
(eg, telephone consultation only). Further studies are required.
Many questions remain to be answered for telemedicine ID con-
sultation, including reimbursement, as state-to-state differences in 
telemedicine coverage remain a barrier to implementation. As the 
field of telemedicine continues to grow, these questions must be 
addressed to provide the best and most efficient care for patients. 
Societal and technological barriers such as access to high-speed 
Internet and video quality have limited telemedicine’s usefulness 
in the past. Although Internet access issues persist in some rural 
areas, progress has been made and video quality has improved. 
High-priority areas of telemedicine research include publishing 
data that are already being collected as part of routine clinical care, 
understanding the use of telemedicine in rural/underserved set-
tings and how it reduces barriers to care and reduces the health 
care disparities therein, and determining how to most efficiently 
deliver care (eg, face-to-face vs e-consult, etc.). Telemedicine ID 
consultation may be a way to reduce inequities and treatment dis-
parities for rural/economically disadvantaged patients, and from 
the perspective of primum non nocere, we must be sure that what 
we are doing is what is best.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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